arrow_back Trending Legislation
Share share

Increasing Diversity in Alzheimer's Disease Research

This act aims to boost participation of ethnic and racial minorities in Alzheimer's disease clinical trials. This will lead to better tailored treatments and diagnostics for diverse populations, potentially improving the quality of life for many affected individuals.
Key points
New research centers will be established in minority-concentrated areas, improving access to studies.
Increased focus on educating and informing minorities about opportunities to participate in clinical trials.
Incentives for minority researchers to lead Alzheimer's disease studies.
Requirement for clinical trials to reflect patient diversity by removing unnecessary exclusion criteria.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
ENACT Act of 2021
Print number: S 1548
Sponsor: Sen. Lujan, Ben Ray [D-NM]
Process start date: 2021-05-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increasing Diversity in Alzheimer's Disease Research

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1548.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-05-11.

What are the main provisions?

Key points include:

  • New research centers will be established in minority-concentrated areas, improving access to studies.
  • Increased focus on educating and informing minorities about opportunities to participate in clinical trials.
  • Incentives for minority researchers to lead Alzheimer's disease studies.
  • Requirement for clinical trials to reflect patient diversity by removing unnecessary exclusion criteria.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Lujan, Ben Ray [D-NM].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 1548

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health